↓ Skip to main content

A modern approach to the treatment of mitochondrial disease

Overview of attention for article published in Current Treatment Options in Neurology, October 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#9 of 499)
  • High Attention Score compared to outputs of the same age (98th percentile)

Mentioned by

news
1 news outlet
blogs
4 blogs
policy
1 policy source
twitter
36 X users
patent
8 patents
facebook
18 Facebook pages
wikipedia
1 Wikipedia page
googleplus
3 Google+ users
reddit
1 Redditor
pinterest
1 Pinner
video
1 YouTube creator

Citations

dimensions_citation
277 Dimensions

Readers on

mendeley
399 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A modern approach to the treatment of mitochondrial disease
Published in
Current Treatment Options in Neurology, October 2009
DOI 10.1007/s11940-009-0046-0
Pubmed ID
Authors

Sumit Parikh, Russell Saneto, Marni J. Falk, Irina Anselm, Bruce H. Cohen, Richard Haas, The Mitochondrial Medicine Society

Abstract

The treatment of mitochondrial disease varies considerably. Most experts use a combination of vitamins, optimize patients' nutrition and general health, and prevent worsening of symptoms during times of illness and physiologic stress. We agree with this approach, and we agree that therapies using vitamins and cofactors have value, though there is debate about the choice of these agents and the doses prescribed. Despite the paucity of high-quality scientific evidence, these therapies are relatively harmless, may alleviate select clinical symptoms, and theoretically may offer a means of staving off disease progression. Like many other mitochondrial medicine physicians, we have observed significant (and at times life-altering) clinical responses to such pharmacologic interventions. However, it is not yet proven that these therapies truly alter the course of the disease, and some experts may choose not to use these medications at all. At present, the evidence of their effectiveness does not rise to the level required for universal use. Based on our clinical experience and judgment, however, we agree that a therapeutic trial of coenzyme Q10, along with other antioxidants, should be attempted. Although individual specialists differ as to the exact drug cocktail, a common approach involves combinations of antioxidants that may have a synergistic effect. Because almost all relevant therapies are classified as medical foods or over-the-counter supplements, most physicians also attempt to balance the apparent clinical benefit of mitochondrial cocktails with the cost burden that these supplements pose for the family.

X Demographics

X Demographics

The data shown below were collected from the profiles of 36 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 399 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 8 2%
United Kingdom 3 <1%
Australia 1 <1%
Finland 1 <1%
India 1 <1%
Portugal 1 <1%
Germany 1 <1%
Czechia 1 <1%
Spain 1 <1%
Other 1 <1%
Unknown 380 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 55 14%
Student > Bachelor 54 14%
Researcher 50 13%
Student > Master 47 12%
Other 30 8%
Other 86 22%
Unknown 77 19%
Readers by discipline Count As %
Medicine and Dentistry 106 27%
Agricultural and Biological Sciences 63 16%
Biochemistry, Genetics and Molecular Biology 41 10%
Nursing and Health Professions 23 6%
Neuroscience 15 4%
Other 60 15%
Unknown 91 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 73. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 April 2024.
All research outputs
#599,850
of 25,805,386 outputs
Outputs from Current Treatment Options in Neurology
#9
of 499 outputs
Outputs of similar age
#1,384
of 107,049 outputs
Outputs of similar age from Current Treatment Options in Neurology
#1
of 3 outputs
Altmetric has tracked 25,805,386 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 499 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 107,049 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them